ArticleAlimentary pharmacology & therapeutics2022
Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Targeting IBD treatment: smart drug delivery systems for oral administration.Materials today. Bio · 2026Review
- Clots in colitis: Thromboembolism and beyond.World journal of clinical cases · 2025Article
- Network analysis of extraintestinal manifestations and associated autoimmune disorders in Crohn's disease and ulcerative colitis.NPJ digital medicine · 2025Article
- Risk of malnutrition increases in the year prior to surgery among patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2025Article
- Risk of heart failure in inflammatory bowel disease: a Swedish population-based study.European heart journal · 2024Article
- Portal vein thrombosis as extraintestinal complications of Crohn's disease: a case report and review of literature.Journal of medical case reports · 2024Review
- All-cause mortality of hospitalized inflammatory bowel disease patients: a multicenter study from Iran.Gastroenterology and hepatology from bed to bench · 2024Article
- Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.Journal of health economics and outcomes research · 2024Article
- Subtypes of Venous Thromboembolism in Inflammatory Bowel Disease: A Nationwide Assessment.Clinical research and clinical trials · 2024Article
- Uncovering novel therapeutic clues for hypercoagulable active ulcerative colitis: novel findings from old data.Gastroenterology report · 2024Article
- Cardiovascular manifestations of inflammatory bowel diseases and the underlying pathogenic mechanisms.American journal of physiology. Regulatory, integrative and comparative physiology · 2023Review
- Immune-mediated inflammatory diseases and risk of venous thromboembolism: A Mendelian randomization study.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundVenous thromboembolism (VTE) is a significant cause of morbidity and mortality among patients with inflammatory bowel disease (IBD). However, data on national trends remain limited.
aimsTo assess national trends in VTE-associated hospitalisations among patients with IBD as well as risk factors for, and mortality associated with, these events
methodsUsing the U.S. Nationwide Inpatient Sample from 2000-2018, temporal trends in VTE were assessed using the National Cancer Institute's Joinpoint Regression Program with estimates presented as the average annual percent change (AAPC) with 95% confidence intervals (CIs).
resultsBetween 2000 and 2018, there were 4,859,728 hospitalisations among patients with IBD, with 128,236 (2.6%) having a VTE, and 6352 associated deaths. The rate of VTE among hospitalised patients with IBD increased from 192 to 295 cases per 10,000 hospitalisations (AAPC 2.4%, 95%CI 1.4%, 3.4%, p < 0.001), and remained significant when stratified by ulcerative colitis (UC) and Crohn's disease as well as by deep vein thrombosis and pulmonary embolism. On multivariable analysis, increasing age, male sex, UC (aOR: 1.30, 95%CI 1.26, 1.33), identifying as non-Hispanic Black, and chronic corticosteroid use (aOR: 1.22, 95%CI 1.16, 1.29) were associated with an increased risk of a VTE-associated hospitalisation.
conclusionRates of VTE-associated hospitalisations are increasing among patients with IBD. Continued efforts need to be placed on education and risk reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.